07:00 , Oct 21, 2013 |  BC Week In Review  |  Clinical News

Parsatuzumab: Development discontinued

Roche disclosed in its 3Q13 update that it discontinued development of parsatuzumab after the compound as first-line treatment of metastatic non-small cell lung cancer (NSCLC) missed the primary endpoint of improving PFS in the Phase...
00:23 , Oct 18, 2013 |  BC Extra  |  Financial News

Roche reports 3Q13 sales of new cancer drugs

Roche (SIX:ROG; OTCQX:RHHBY) reported 3Q13 revenues on Thursday, including sales for its two newest drugs for HER2-positive metastatic breast cancer. The pharma recorded sales of CHF78 million ($85.8 million) in worldwide 3Q13 sales of breast...
08:00 , Nov 17, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer EGF-like-domain multiple 7 (EGFL7) Studies in mice suggest inhibiting EGFL7 could help treat cancer. In mice with xenograft breast cancer...
07:00 , Aug 3, 2009 |  BC Week In Review  |  Clinical News

RG7414: Phase Ia started

Roche disclosed that last quarter it began a dose-escalation Phase Ia trial to evaluate RG7414 in patients. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland   Product: RG7414   Business: Cancer   Molecular target: EGF-like-domain multiple 7 (EGFL7)...